A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma A/S is seeking a Senior Director, Global Marketing Strategy to translate brand strategy into customer engagement and multichannel go-to-market plans. You will build a scalable marketing organization and serve as the commercial voice shaping core brands ahead of a major obesity/metabolic health launch.
The role owns marketing planning, budgeting and performance, partners with Medical Affairs and Legal to ensure compliant promotional activities, and collaborates across Commercial,
Does it excite you to build the marketing engine for an upcoming obesity and metabolic health launch, and do you have experience with turning brand strategy into integrated, compliant go-to-market plans? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position: Senior Director, Global Marketing Strategy, you will build and lead the marketing capabilities that bring Zealand Pharma’s medicines to healthcare professionals and patients.
The role translates brand strategy into customer engagement, channel, and campaign plans, and creates the foundation for a scalable marketing organization. You will be the commercial voice in building the core brands towards a successful launch.
You will be a member of the global commercial organization reporting into the Senior Vice President. You will be part of building the area and will work closely with our external partners and with key stakeholders, e.g. Medical Affairs, R&D, Market Access, Alliance Management.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Deadline: 15 November 2026.
For further information, please contact Senior Vice President Mette Zacho, MZacho@zealandpharma.com.
A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.